1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Zimbabwe Pharmaceuticals and Healthcare Report Q1 2016

Zimbabwe Pharmaceuticals and Healthcare Report Q1 2016

  • December 2015
  • -
  • Business Monitor International
  • -
  • 66 pages

Includes 3 FREE quarterly updates

BMI View: Although the government's ambition to develop a national health insurance scheme to facilitateuniversal health coverage is a positive step, Zimbabwe's healthcare system, in its current state, is heavilydependent on donor funds, owing to past failures to sufficiently finance its health sector Global recession ispresenting a significant risk as the availability of funds from foreign organisations dries up Politicalinstability and a grim economic outlook enforce our view that Zimbabwe will remain an unattractive marketfor multinational drugmakersHeadline Expenditure ProjectionsPharmaceuticals: USD361mn in 2014 to USD380mn in 2015; +52% in US dollar terms Forecastunchanged from last quarter

Table Of Contents

Zimbabwe Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Zimbabwe 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Zimbabwe 2011-2019) 12
Healthcare Market Forecast 13
Prescription Drug Market Forecast 14
Patented Drug Market Forecast 15
Generic Drug Market Forecast 15
Pharmaceutical Trade Forecast 16
Table: Pharmaceutical Trade Data And Forecasts (Zimbabwe 2013-2019) 18
Industry Risk/Reward Index 19
Middle East and Africa Risk/Reward Index - Q1 2016 19
Zimbabwe Risk/Reward Index 27
Rewards 27
Risks 27
Regulatory Review 29
Regulatory Regime 29
Intellectual Property Developments 31
Counterfeit Drugs 32
Pricing And Reimbursement Regimes 32
Public Drug Procurement 33
Market Overview 35
Epidemiology 36
Healthcare Sector 38
Table: Zimbabwe: Healthcare Facilities 39
Healthcare Funding 40
Health Insurance 42
Healthcare Staff 43
Traditional Medicine 44
Biotechnology 44
Clinical Trials 45
Competitive Landscape 46
Pharmaceutical Industry 46
Domestic Industry 47
Foreign Industry 47
Pharmaceutical Sector Developments 48
Retail Pharmacy Sector 49
Company Profile 50
Datlabs 50
Varichem Laboratories 52
Demographic Forecast 55
Table: Population Headline Indicators (Zimbabwe 1990-2025) 56
Table: Key Population Ratios (Zimbabwe 1990-2025) 56
Table: Urban/Rural Population and Life Expectancy (Zimbabwe 1990-2025) 57
Table: Population By Age Group (Zimbabwe 1990-2025) 57
Table: Population By Age Group % (Zimbabwe 1990-2025) 58
Glossary 60
Methodology 62
Pharmaceutical Expenditure Forecast Model 62
Healthcare Expenditure Forecast Model 62
Notes On Methodology 63
Risk/Reward Index Methodology 64
Index Overview 65
Table: Pharmaceutical Risk/Reward Index Indicators 65
Indicator Weightings 66

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.